Nektar Therapeutics

NKTR

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000906709

E

weakest fifth of 370 graded peers in healthcare

rank 361 of 370; percentile 97.6; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard

Profitability	D/E percentile 81.8
Solvency	C/D percentile 61.4
Growth and financing	E percentile 88.3
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $280.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 13, 2026 239 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$37.23 2026-11-06; market equity $1.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 13, 2026

Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. We apply our deep understanding of immunology to identify and create innovative drug candidates and use our drug development expertise to advance these molecules through preclinical and clinical development.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 81.8						
Gross profitability	19.7%	32.3%		64.8	365	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	15.2%	(6.6%)	93.4	802	2025-12-31
Gross margin stability, five years	12.7 pts	2.8 pts	87.1	242	2025-12-31
Solvency, sleeve percentile 61.4					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(41.60)	(0.37)	86.2	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	4.97x	2.94x	36.6	828	2025-12-31
Growth and financing, sleeve percentile 88.3					
Revenue growth, three-year compound	(15.7%)	10.0%	88.1	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(26.7%)	2.2%	90.9	696	2025-12-31
Net share issuance, one year	131.2%	2.5%	86.0	630	2026-03-11

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 131.2%
Short runway	cash runway is 2.0 months

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
356	Bolt Biotherapeutics, Inc. (BOLT)	96.2	E	short runway, distress
357	Pfizer Inc. (PFE)	96.5	E	
358	Clene Inc. (CLNN)	96.7	E	dilution
359	Dare Bioscience, Inc. (DARE)	97.0	E	dilution
360	Longeveron Inc. (LGVN)	97.3	E	short runway
361	Nektar Therapeutics (NKTR)	97.6	E	dilution, short runway
362	Agenus Inc. (AGEN)	97.8	E	dilution
363	Vyome Holdings, Inc. (HIND)	98.1	E	dilution, late filer, fortress balance sheet
364	Sintx Technologies, Inc. (SINT)	98.4	E	dilution, short runway
365	Coherus Oncology, Inc. (CHRS)	98.6	E	dilution, short runway
366	Atara Biotherapeutics, Inc. (ATRA)	98.9	E	dilution, short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(6.8%)	(2.1%)	45
Distance from 52-week high	(62.9%)	(30.5%)	17
EBIT to enterprise value	(10.3%)	(1.5%)	34
Free cash flow yield	(16.4%)	(1.0%)	26
Book value to price	0.71	0.29	78
Sales to price	0.04	0.30	15
Composite equity issuance, five years	103.4%	21.4%	76
Relative strength against the sector, log excess return	(0.24)	(0.19)	45

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$39.3M
Operating cash flow, four quarters	-$233.8M
Months of runway	2.0
Days since last periodic filing	85 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$44.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$55.2M	2025-12-31	2026-03-13	10-K	26-104547
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$0	2025-12-31	2026-03-13	10-K	26-104547
3	assets	us-gaap:Assets	$280.4M	2025-12-31	2026-03-13	10-K	26-104547
4	net income	us-gaap:NetIncomeLoss	-$164.1M	2025-12-31	2026-03-13	10-K	26-104547
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$208.5M	2025-12-31	2026-03-13	10-K	26-104547
6	assets	us-gaap:Assets	$303.9M	2024-12-31	2026-03-13	10-K	26-104547
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$98.4M	2024-12-31	2026-03-13	10-K	26-104547
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$30.7M	2024-12-31	2026-03-13	10-K	26-104547
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$90.1M	2023-12-31	2025-03-14	10-K	25-039389
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$33.8M	2023-12-31	2025-03-14	10-K	25-039389
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$92.1M	2022-12-31	2024-03-05	10-K	24-026249
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$21.6M	2022-12-31	2024-03-05	10-K	24-026249
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$101.9M	2021-12-31	2024-03-05	10-K	24-026249
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$24.9M	2021-12-31	2024-03-05	10-K	24-026249
15	current assets	us-gaap:AssetsCurrent	$266.3M	2025-12-31	2026-03-13	10-K	26-104547
16	current liabilities	us-gaap:LiabilitiesCurrent	$53.5M	2025-12-31	2026-03-13	10-K	26-104547
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$3.8B	2025-12-31	2026-03-13	10-K	26-104547
18	operating income	us-gaap:OperatingIncomeLoss	-$140.1M	2025-12-31	2026-03-13	10-K	26-104547

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	book equity	us-gaap:StockholdersEquity	$89.8M	2025-12-31	2026-03-13	10-K	26-104547
20	liabilities	us-gaap:Liabilities	$190.6M	2025-12-31	2026-03-13	10-K	26-104547
21	operating income	us-gaap:OperatingIncomeLoss	-$376.2M	2022-12-31	2024-03-05	10-K	24-026249
22	interest expense	us-gaap:InterestExpense	$0	2022-12-31	2023-02-28	10-K	23-000004
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$171,000	2025-12-31	2026-03-13	10-K	26-104547
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$175.7M	2024-12-31	2026-03-13	10-K	26-104547
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.5M	2024-12-31	2026-03-13	10-K	26-104547
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$192.6M	2023-12-31	2025-03-14	10-K	25-039389
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$865,000	2023-12-31	2025-03-14	10-K	25-039389
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$304.0M	2022-12-31	2024-03-05	10-K	24-026249
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.7M	2022-12-31	2024-03-05	10-K	24-026249
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$4.1M	2024-12-31	2025-03-14	10-K	25-039389
31	operating income	us-gaap:OperatingIncomeLoss	-$105.2M	2024-12-31	2026-03-13	10-K	26-104547
32	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$119.2M	2024-12-31	2026-03-13	10-K	26-104547
33	income tax	us-gaap:IncomeTaxExpenseBenefit	-$239,000	2024-12-31	2026-03-13	10-K	26-104547
34	current assets	us-gaap:AssetsCurrent	$261.3M	2024-12-31	2026-03-13	10-K	26-104547
35	current liabilities	us-gaap:LiabilitiesCurrent	$61.4M	2024-12-31	2026-03-13	10-K	26-104547
36	current assets	us-gaap:AssetsCurrent	$330.7M	2023-12-31	2025-03-14	10-K	25-039389
37	current liabilities	us-gaap:LiabilitiesCurrent	$51.3M	2023-12-31	2025-03-14	10-K	25-039389
38	assets	us-gaap:Assets	$398.0M	2023-12-31	2025-03-14	10-K	25-039389
39	assets	us-gaap:Assets	$710.6M	2022-12-31	2024-03-05	10-K	24-026249
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	28,687,963	2026-03-11	2026-03-13	10-K	26-104547
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	186,103,588	2025-02-27	2025-03-14	10-K	25-039389

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.